Roggwil, May 9, 2023 – The first series of the tinnitus therapy device tinniwell for the Asian market was produced in record time and will be delivered this month. The management of Resaphene is currently negotiating with other medical technology distributors about the granting of additional country licenses. Since the markets no longer have to be opened up themselves, sales growth can increase exponentially.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668